التفاصيل البيبلوغرافية
| العنوان: |
Evidence-based management of COVID-19 in cancer patients: Guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). |
| المؤلفون: |
Giesen, Nicola1 (AUTHOR) nicola.giesen@med.uni-heidelberg.de, Sprute, Rosanne2,3 (AUTHOR), Rüthrich, Maria4,5 (AUTHOR), Khodamoradi, Yascha6 (AUTHOR), Mellinghoff, Sibylle C.2,3 (AUTHOR), Beutel, Gernot7,8 (AUTHOR), Lueck, Catherina7,8 (AUTHOR), Koldehoff, Michael8,9 (AUTHOR), Hentrich, Marcus10 (AUTHOR), Sandherr, Michael11 (AUTHOR), von Bergwelt-Baildon, Michael8,12 (AUTHOR), Wolf, Hans-Heinrich13 (AUTHOR), Hirsch, Hans H.14,15,16 (AUTHOR), Wörmann, Bernhard17 (AUTHOR), Cornely, Oliver A.1,2,3 (AUTHOR), Köhler, Philipp1,2,3 (AUTHOR), Schalk, Enrico1,8,18 (AUTHOR), von Lilienfeld-Toal, Marie1,4,5 (AUTHOR) |
| المصدر: |
European Journal of Cancer. Nov2020, Vol. 140, p86-104. 19p. |
| مصطلحات موضوعية: |
*ANTINEOPLASTIC agents, *CANCER patients, *PREVENTION of communicable diseases, *MEDICAL protocols, *EVIDENCE-based medicine, *COVID-19, *COVID-19 pandemic |
| مستخلص: |
Since its first detection in China in late 2019 the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the associated infectious disease COVID-19 continue to have a major impact on global healthcare and clinical practice. Cancer patients, in particular those with haematological malignancies, seem to be at an increased risk for a severe course of infection. Deliberations to avoid or defer potentially immunosuppressive therapies in these patients need to be balanced against the overarching goal of providing optimal antineoplastic treatment. This poses a unique challenge to treating physicians. This guideline provides evidence-based recommendations regarding prevention, diagnostics and treatment of SARS-CoV-2 infection and COVID-19 as well as strategies towards safe antineoplastic care during the COVID-19 pandemic. It was prepared by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO) by critically reviewing the currently available data on SARS-CoV-2 and COVID-19 in cancer patients applying evidence-based medicine criteria. • Cancer patients are vulnerable to severe acute respiratory syndrome coronavirus 2 infection and severe COVID-19. • Comprehensive management strategies are required in care for cancer patients. • Evidence-based recommendations help clinicians make informed treatment decisions. • Providing state-of-the-art cancer care is possible during COVID-19 pandemic. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
